Tenax Therapeutics Reports Third Quarter 2026 Financial Results
Tenax Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $16.7 million and providing updates on its clinical development programs.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Tenax Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $16.7 million and providing updates on its clinical development programs.
Pomerantz LLP has filed a class action lawsuit against Tenax Therapeutics, Inc. and certain officers, alleging the company made false and misleading statements regarding its business and the efficacy of its drug candidate, TNX-103.
Tenax Therapeutics, Inc. filed a statement of changes in beneficial ownership of securities regarding ADAR1 Capital Management, LLC on October 21, 2026.
https://www.sec.gov/Archives/edgar/data/34956/000119312526417939/d139658dex991.htm
Filed: 2026-10-08 AccNo: 0001193125-26-417939 Size: 4 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits